OnKure Therapeutics Inc. Class A (OKUR)
NASDAQ: OKURHealth CareBiotechnology: Pharmaceutical PreparationsUSD
At close: Nov 20, 4:00 PM ET · Delayed 15 min
OKUR stock chart
Technical analysisKey statistics
All statistics- Market cap
- $111.21M
- EPS (TTM)
- -$2.26
- Dividend yield
- None
- 52-week range
- 2.01 – 5.38
- Day range
- 2.68 – 2.81
- Volume / Avg
- 195.21K / 335.78K
- Beta
- —
- Shares outstanding
- 40.50M
52-week range
OKUR stock today
Shares of OnKure Therapeutics (OKUR) finished lower on Nov 20 at $2.70, a drop of 2.17% or $0.06 per share, versus the S&P 500's 3.70% decline. Shares are 49.8% below their 52-week high of $5.38, set on May 1, 2026 and 34.3% above the 52-week low of $2.01, in the middle of the past year's range. OKUR is down 6.9% year to date, underperforming the S&P 500 (+1.2%). Over the past 12 months, the stock has gained 4.7%.
OnKure Therapeutics has posted a net loss over the last twelve months (EPS of -$2.26), so its P/E ratio is not meaningful.
Summary generated from market data by MetaCap's automated system. Methodology
About OnKure Therapeutics
Company profileOnKure Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of precision medicines that target biologically validated drivers of cancers and other diseases. Its lead product candidate includes OKI-219, a selective inhibitor of phosphoinositide 3-kinase alpha (PI3Ka) harboring the H1047R mutation that is in Phase 1 clinical trial for the treatment of solid tumors, including breast cancer. The company was founded in 2011 and is headquartered in Boulder, Colorado.
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- CEO
- Dr. Nicholas A. Saccomano Ph.D.
- Headquarters
- Boulder, CO
- Employees
- 45
- IPO year
- 2021
- Website
- onkuretherapeutics.com
Financial highlights
Full financialsOnKure Therapeutics reported a net loss of $59.5 million, compared with a loss of $52.7 million a year earlier. Diluted earnings per share came in at -$4.40.
| Fiscal year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| Revenue | — | $0 | — | — | — |
| Growth | — | — | — | — | — |
| Net income | $-59.52M | $-52.67M | $-35.31M | $-51.95M | $-39.77M |
| EPS (diluted) | $-4.40 | $-15.28 | $-124.41 | $-2.12 | $-2.19 |
Analyst forecast
ForecastConsensus (6 analysts)
none
Avg. price target
$15.25+464.81%
- Strong buy 0
- Buy 5
- Hold 1
- Sell 0
- Strong sell 0
Target range
Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.
Earnings
Earnings history- Last reported (Sep/2026)
- Nov 5, 2026
- EPS actual vs est.
- $-0.36 vs $-0.29
- Surprise
- -24.14%
OKUR news
All OKUR newsOnKure Therapeutics peers
Health Care sector| Company | Price | % Chg | Market cap | Compare |
|---|---|---|---|---|
| IMUXImmunic Inc. | 6.99 | -5.41% | $111.01M | vs OKUR |
| MENSJyong Biotech Ltd. | 1.45 | -17.14% | $110.24M | vs OKUR |
| SPRBSpruce Biosciences Inc. | 38.00 | -6.15% | $109.21M | vs OKUR |
| BGMBGM Group Ltd. Class A | 8.13 | 0.00% | $108.57M | vs OKUR |
| AKBAAkebia Therapeutics Inc. | 0.3855 | -8.71% | $107.04M | vs OKUR |
| ADAGAdagene Inc. ADR | 1.76 | -12.44% | $118.17M | vs OKUR |
| GNLXGenelux Corporation | 2.17 | -4.82% | $103.36M | vs OKUR |
| FHTXFoghorn Therapeutics Inc. | 1.72 | -3.37% | $103.14M | vs OKUR |
Indexes, lists and sector
OnKure Therapeutics stock FAQ
What is OnKure Therapeutics's stock price today?
OKUR last traded at $2.70 as of Nov 20, 4:00 PM EST, down 2.17% on the day. Prices are delayed at least 15 minutes.
Does OnKure Therapeutics pay a dividend?
No. OnKure Therapeutics does not currently pay a regular cash dividend.
Who is OnKure Therapeutics's CEO?
Dr. Nicholas A. Saccomano Ph.D. is the chief executive officer of OnKure Therapeutics Inc. Class A, which has about 45 employees.
Has OKUR ever split its stock?
Yes. The most recent OKUR stock split was a 1-for-10 split on Oct 7, 2024.
What is the OKUR 52-week high?
The 52-week high for OKUR is $5.38 and the 52-week low is $2.01. The stock is currently 49.8% below its high.